Consumer Insights - During the New Year holiday, 142 million domestic trips were made, representing a year-on-year increase of 5.19% compared to 2024, with total spending reaching 84.789 billion yuan, up 6.35%[16] - Hainan's duty-free shopping saw a significant boost, with the number of shoppers increasing by 27.09% and total spending rising by 49.89% compared to the same period in 2024[18] - In major cities, Shanghai's daily average consumption during the holiday was 12.2 billion yuan, a 2.5% increase year-on-year, while Beijing's monitored sales reached 4.04 billion yuan, up 16.3%[17] High-end Manufacturing - The "Justice Mission-2025" military exercise highlights the strategic importance of the military-industrial sector amid geopolitical tensions, emphasizing its role in national sovereignty and external risk management[20][26] - The military exercise's focus on Taiwan reflects a more precise and targeted approach compared to previous drills, enhancing control over critical maritime routes and deterring external interference[22] Hard Technology - Major domestic wafer manufacturers are actively engaging in capital operations, with SMIC's registered capital increasing from $6.5 billion to $10.0773 billion, and a planned acquisition of 49% of SMIC North for 40.601 billion yuan[27][33] - Longxin Technology's IPO aims to raise 29.5 billion yuan, potentially becoming the second-largest fundraising in the Sci-Tech Innovation Board's history, supporting its expansion in memory chip production[27][31] Health Sector - Domestic small nucleic acid drug companies, such as Rebio and Bowang Pharmaceutical, are demonstrating strong R&D capabilities, with multiple products entering clinical phases and significant business development collaborations underway[35][36]

Group 1 - MiniMax has officially launched its IPO in Hong Kong, with a total of 25.39 million shares to be issued at a price range of HKD 151 to HKD 165 per share, aiming to raise funds for AI model and product development [1] - MiniMax is recognized as one of the "top four global full-modal companies," with a user base exceeding 200 million, covering both B2C and B2B AI native products [1] Group 2 - Rebio Biotech has initiated its IPO in Hong Kong, planning to issue 27.49 million H-shares at a price of HKD 57.97 per share, with 10% allocated for Hong Kong and 90% for international sales [2] - The company focuses on small nucleic acid drug research, particularly in siRNA therapies, with its core product RBD4059 aimed at treating thrombotic diseases [2] Group 3 - BlueFocus Communication Group has submitted its second listing application to the Hong Kong Stock Exchange, with a focus on providing technology-driven marketing services across various industries [3] - The company aims to leverage its position as a leading marketing firm in China to enhance its global and AI-native business through the upcoming IPO [3] Group 4 - Longqi Technology has passed the listing hearing at the Hong Kong Stock Exchange, being recognized as a leading provider of smart products and services, with significant market shares in both consumer electronics and smartphone ODM sectors [4] - The company holds a 22.4% market share in the global consumer electronics ODM market and a 32.6% share in the smartphone ODM market, indicating its strong industry position [4]

Core Viewpoint - The launch of Rebio Biotech on the Hong Kong Stock Exchange marks a significant entry into the Chinese innovative drug industry, particularly in the small RNA field, with a share price set at HKD 57.97 and a listing date of January 9, 2026. The company has attracted notable institutional investors, indicating strong market interest [1][2]. Group 1: Industry Context - The global pharmaceutical innovation is transitioning into the "nucleic acid era," with small RNA drugs emerging as a disruptive treatment paradigm, following small molecules and antibody drugs [1]. - The industry is at a critical turning point, moving from "scientific breakthroughs" to "commercial realization," particularly in the siRNA sector [3]. Group 2: Company Positioning - Rebio Biotech is one of the few companies globally with comprehensive self-research capabilities in small RNA drugs, covering the entire process from target discovery to clinical development [1]. - The company has established a fully autonomous research and production platform, positioning itself to compete internationally and define new treatment standards [1][6]. Group 3: Product Pipeline and Validation - The company’s core products, RBD4059 and RBD5044, are strategically positioned in validated therapeutic areas, reducing development risks and enhancing commercial prospects [10][11]. - RBD4059 targets coagulation factor XI (FXI) and aims to transform anticoagulation therapy, while RBD5044 targets APOC3 for treating hypertriglyceridemia, benefiting from established regulatory pathways [10][11]. Group 4: Technological and Operational Strengths - Rebio's proprietary delivery systems, such as RiboGalSTAR™, have been clinically validated, providing a competitive edge and expanding the application of siRNA therapies beyond liver diseases [9]. - The company has established a clinical trial base in Sweden, ensuring compliance with international standards and facilitating entry into major markets [13]. Group 5: Financial Performance and Growth Potential - The company reported a revenue of CNY 104 million in the first half of 2025, a year-on-year increase of 56.57%, with a reduction in losses by 30.94%, indicating accelerating commercialization capabilities [6]. - The upcoming IPO funding will primarily support global clinical research for core products and enhance technology platform development, facilitating the transition from clinical to commercial stages [18][20]. Group 6: Strategic Collaborations - Rebio has secured strategic partnerships with leading pharmaceutical companies, which not only provide funding but also validate its technological capabilities [14]. - The company retains rights to overseas markets in its licensing agreements, highlighting its focus on global value realization [14]. Group 7: Future Outlook - The dual strategy of advancing proprietary products and engaging in platform licensing is expected to create a sustainable revenue model, enhancing financial stability and supporting ongoing research [17][18]. - Rebio Biotech is positioned for a systematic value reassessment as it combines technology, product pipeline, and international operational capabilities, making it a unique player in the biotechnology sector [20].

Core Insights - In 2025, China's pharmaceutical and healthcare industry enters a critical phase driven by "innovation deepening + global breakthrough," with emerging therapies like small nucleic acids, PROTAC, and CGT accelerating from clinical validation to commercialization [2][34] - The reports from the top ten Chinese securities firms provide authoritative insights into technological iterations, industry trends, and globalization strategies, serving as a guide for industry practitioners and investors [2][34] Group 1: Small Nucleic Acids - 2025 is a pivotal year for small nucleic acid drugs, driven by technological breakthroughs and expanding indications from rare diseases to chronic diseases like hyperlipidemia and hypertension [4][36] - The small nucleic acid sector is expected to see a surge in catalysts, including the commercialization of major products like Novartis' Inclisiran and the approval of Alnylam's Vutrisiran and Fitusiran [5][37] - The market for small nucleic acids is projected to reach approximately $30 billion, with significant growth anticipated in CNS diseases [10][42] Group 2: Brain-Computer Interface - The brain-computer interface industry is accelerating innovation with three main technical paths: invasive, semi-invasive, and non-invasive, each with distinct advantages and challenges [7][39] - The global brain-computer interface market is expected to reach approximately $2.6 billion by 2024, with a CAGR of about 13% from 2023 to 2027 [7][39] Group 3: PROTAC - PROTACs are gaining traction as targeted protein degradation drugs, with advantages such as high oral bioavailability and broad target range, making them popular in oncology and autoimmune disease research [19][51] - The first BTK PROTAC has entered Phase III trials, showcasing promising efficacy and safety data [19][51] Group 4: Chinese Innovative Drugs - Chinese innovative drugs are entering a "DeepSeek" moment, with domestic companies increasingly recognized overseas, and the number of license-out projects surpassing license-in projects for the first time in 2023 [16][48] - The market for innovative drugs in China is expected to exceed 2 trillion RMB by 2030, with a CAGR of 24.1% [29][63] Group 5: Peripheral Intervention Industry - The peripheral intervention industry is experiencing rapid growth, with a significant patient base and low treatment penetration compared to international standards [25][57] - The market for peripheral artery interventions is projected to grow at a CAGR of 15.6% from 2021 to 2030, while peripheral venous interventions may see a CAGR of 29.3% [25][57] Group 6: Weight Loss and Diabetes Treatment - The market for GLP-1RA drugs, such as semaglutide and tirzepatide, is expected to exceed $150 billion by 2031, with significant business development opportunities emerging for domestic companies [26][58] - Multi-target drug development is anticipated to overcome the limitations of single-target therapies, enhancing efficacy in weight loss and metabolic health [26][58]

Core Viewpoint - The pharmaceutical sector experienced a strong rally on the 26th, particularly in innovative drugs and vaccine concepts, with several companies seeing significant stock price increases [1] Industry Summary - Recent advancements in the small nucleic acid drug field have garnered significant attention from both the industry and investors, marking a transition from concept validation to the brink of industrial rise [1] - By 2025, breakthroughs in delivery technology are expected to expand indications from the liver to cardiovascular and CNS areas, coupled with the commercialization of major products and substantial mergers by multinational pharmaceutical giants, indicating a golden development period driven by "technological breakthroughs + commercial realization" [1] - According to Everbright Securities, domestic pharmaceutical companies are accelerating their R&D progress, with many entering clinical research phases since 2025. The focus should be on leading innovative drug companies with advanced technology platforms and differentiated pipelines, as well as innovative industry chain companies likely to benefit from the overall industry upturn [1] - The investment approach in the pharmaceutical sector should increasingly emphasize the clinical value logic, addressing clinical needs of patients and doctors, influenced by domestic medical insurance policies and global expansion strategies, which are assigning higher premiums to clinical value [1] - From the perspective of clinical value, the innovative drug industry chain and innovative medical devices are viewed positively [1]

Core Viewpoint - The pharmaceutical sector experienced a strong rally on the 26th, particularly in innovative drugs and vaccine concepts, with several companies seeing significant stock price increases [1] Industry Summary - Recent advancements in the small nucleic acid drug field have garnered significant attention from both the industry and investors, marking a transition from concept validation to the brink of industrial rise [1] - Since 2025, breakthroughs in delivery technology are expected to expand indications from the liver to cardiovascular and CNS areas, coupled with the commercialization of major products and substantial mergers by multinational pharmaceutical giants, indicating a golden development period driven by "technological breakthroughs + commercial realization" [1] - According to Everbright Securities, domestic pharmaceutical companies are accelerating their R&D progress, with many entering clinical research phases since 2025. The focus should be on leading innovative drug companies with advanced technology platforms and differentiated pipelines, as well as innovative industry chain companies likely to benefit from the overall industry upturn [1] - The investment approach in the pharmaceutical sector should increasingly emphasize the clinical value logic, addressing clinical needs of patients and doctors, influenced by domestic medical insurance policies and global expansion strategies, which are assigning higher premiums to clinical value [1] - From the perspective of clinical value, the innovative drug industry chain and innovative medical devices are viewed positively [1]

Group 1: Fixed Income Market - The main economic indicators weakened in October, leading to expectations of interest rate cuts and reserve requirement ratio reductions to support the economy [7] - The three pillars supporting the economy are under pressure, with negative growth in infrastructure and real estate investments [7] - The central bank has indicated the need for counter-cyclical and cross-cyclical adjustments, suggesting that policy rate cuts and new tools may be key to economic support in the coming months [7] Group 2: Pharmaceutical Industry - The small nucleic acid drug market is expected to grow significantly, with a projected market size of approximately $62 billion in 2024 and $467 billion by 2033, reflecting a compound annual growth rate of 25% [12] - Alnylam Pharmaceuticals is a leader in the siRNA field, with strong commercialization performance and a revenue of $2.617 billion in the first three quarters of 2025, a 58% year-on-year increase [13] - The industry is characterized by a high degree of activity in business development transactions, with over $45 billion in cumulative transactions in the siRNA sector from 2018 to November 2025 [12] Group 3: Consumer Electronics - The 2025 "Double Eleven" shopping festival saw a total e-commerce sales of 1.695 trillion yuan, a year-on-year increase of 14.2%, with the home appliance sector showing resilience and growth [14][15] - Home appliances accounted for 266.8 billion yuan in sales during the event, representing a 38.2% increase year-on-year, indicating a shift towards smart and integrated appliances [15] - Companies like Haier, Midea, and TCL achieved significant sales milestones, with over 10 billion yuan in transactions during the festival [15] Group 4: Transportation Industry - The express delivery sector experienced record volumes during the "Double Eleven" period, with 13.938 billion packages collected, marking a 117.8% increase in daily average volume compared to regular operations [20] - The oil transportation market is expected to strengthen in December, with VLCC daily earnings reaching $124,000, the highest since Q2 2020, driven by increased demand from the Middle East and Brazil [22] - The logistics sector is benefiting from improved collaboration with e-commerce platforms, enhancing operational efficiency and supporting consumer demand [20] Group 5: Precious Metals - The precious metals market is poised for potential upward movement, with gold prices recently rebounding but not surpassing previous highs, influenced by the end of the U.S. government shutdown and upcoming economic data releases [36][38] - Gold and silver prices have shown recent increases, with gold reaching $4,071.10 per ounce and silver at $52.01 per ounce, reflecting market reactions to economic conditions [35] - The market is closely monitoring key upcoming economic reports, including non-farm payrolls and GDP revisions, which could impact precious metal prices [38]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The trend of Chinese innovative drugs going overseas is a long-term phenomenon, with external environmental changes having limited impact. In the first half of 2025, there were 72 License-out transactions, exceeding half of the total for 2024, with a total transaction amount 16% higher than in 2024. Notably, there were 16 transactions exceeding $1 billion each [2] - The small nucleic acid drug sector has seen significant breakthroughs, particularly in the treatment of chronic diseases such as hypertension and hyperlipidemia, with major collaborations and potential milestone payments indicating a robust commercial outlook [3] - The trend towards oral autoimmune drugs is gaining attention, with significant partnerships and clinical advancements in this area, highlighting the importance of oral formulations in autoimmune therapies [4] - Recent clinical data on long-acting insulin analogs shows promising weight loss results, with ongoing developments in combination therapies for metabolic diseases, indicating a growing market potential [5] - The CXO sector is gradually recovering, with an increase in License-out transactions serving as a vital funding source for biotech companies, leading to a resurgence in innovation and clinical development [6] - The 2025 national medical insurance negotiations and the commercial insurance innovative drug directory are crucial for companies involved, with a focus on orphan drugs and imported PD-1/L-1 products [7] Summary by Sections Industry Tracking - The pharmaceutical sector has underperformed compared to the CSI 300 index, with a recent weekly decline of 1.20% and a monthly decline of 3.38%, ranking 25th among 31 industry indices [22][26] Industry Trends and Valuation - The pharmaceutical industry index currently has a PE ratio of 39.05, above the five-year historical average of 31.36, indicating a higher valuation compared to historical trends [48][50] Recent Research Achievements - The research team has published several in-depth reports on various pharmaceutical topics, including the growth of the blood products industry and the potential of GLP-1 drugs in chronic disease management [53] Important Policies and News - Recent regulations have been introduced to standardize clinical research and ensure drug traceability, which will impact the pharmaceutical landscape significantly [55][56]

Core Insights - The report highlights the significant advantages of ASIC over GPU in terms of cost-effectiveness and energy efficiency, marking a turning point for ASIC development [2][12] - The increasing penetration of AI is driving a surge in inference demand, expanding the market space for ASICs [3][12] - Domestic cloud providers are making strides in self-developed ASICs, indicating a strong demand in the Chinese AI cloud market [12][13] Summary by Sections ASIC vs. GPU - ASICs are specialized chips tightly coupled with downstream applications, focusing on specific needs like text and video inference, while GPUs are general-purpose chips covering a broader range of applications [2][12] - The energy efficiency of Google's TPU v5 is 1.46 times that of NVIDIA's H200, and Amazon's Trainium2 reduces training costs by 40% compared to GPU solutions [2][12] Market Growth and Demand - The global AI ASIC market is projected to reach $125 billion by 2028, with significant contributions from major clients [3][12] - The demand for inference computing is directly linked to throughput, with ChatGPT's weekly active users reaching 700 million by July 2025, driving the need for increased computational power [3][12] ASIC Design Services - ASIC design requires a high level of specialization, with major service providers like Broadcom and Marvell leading the market [3][12] - Broadcom's collaboration with Google on TPU has been pivotal, leveraging a comprehensive IP system and advanced packaging technologies [3][12] Domestic Developments - Leading Chinese cloud providers are achieving results in self-developed ASICs, with significant orders and advancements in technology [12][13] - The trends of PD separation and super nodes are emerging as key developments in the domestic ASIC landscape [12][13] Industry Outlook - The report anticipates a robust growth trajectory for the ASIC market, driven by increasing AI applications and domestic innovation [12][13]

Summary of Key Points from Conference Call Records Industry: Energy Storage Core Insights and Arguments - **Price Increase**: Energy storage cell prices have been rising continuously since June-July 2025, with average prices for 314/280Ah cells reaching 0.295 RMB/Wh. PCS prices have also increased by 0.005 RMB/W to 0.07 RMB/W, indicating a clear trend of price stabilization in the system end, which is expected to improve profitability across the industry [1][2]. - **Market Demand**: Major battery manufacturers are forecasting a shipment growth of 30-50% for 2026, significantly higher than the market's expectation of over 20% growth. This demand is driven by independent energy storage in China and strong overseas demand [1][2]. - **Profitability**: A surveyed 100MW/200MWh power station in Shandong can achieve annual peak-valley price arbitrage profits of 20 million RMB, doubling from 2023 levels. The market is becoming more optimistic, with investment expectations shifting positively [1]. Supply Side - **Capacity Utilization**: Leading battery manufacturers like CATL, EVE, and Haicheng are operating at full capacity, with significant year-on-year increases in capacity utilization for companies like Ruipu and AVIC [2]. Key Companies - **Haibo Technology**: Expected to see a significant increase in Q3 shipments to 9-10GWh, a 46% increase from the previous quarter. The company’s domestic net profit per unit is 0.02 RMB, while overseas is 0.2 RMB, indicating a tenfold difference [2]. - **EVE Energy**: Plans to expand its energy storage capacity to 80GWh in 2025, 120GWh in 2026, and 150GWh in 2027, with current capacity utilization nearing full [2]. Industry: Small Nucleic Acid Drugs Core Insights and Arguments - **Market Growth**: The global small nucleic acid drug market is projected to reach approximately $5.78 billion in 2024, surpassing $10 billion in 2025, and reaching $25 billion by 2030, with a CAGR of 19.5% [4]. - **Recent Collaborations**: Domestic siRNA leader, Wobang Pharmaceutical, has partnered with Novartis for cardiovascular product development, with a total package worth $5.36 billion [3]. Key Companies - **Yuekang Pharmaceutical**: Has established a leading R&D platform for nucleic acid drugs, with its first siRNA drug YKYY015 approved for clinical trials in China and the US [4]. - **Fuyuan Pharmaceutical**: Developing siRNA drugs targeting hyperlipidemia, with its core project FY101 entering Phase I clinical trials [5]. Industry: Solid-State Batteries Core Insights and Arguments - **Production Milestone**: EVE Energy's solid-state battery production line has been officially launched, with the "Longquan No. 2" all-solid-state battery successfully produced [6]. - **Market Potential**: The solid-state battery market is expected to exceed 100 billion RMB, with significant demand for core equipment and materials [6]. Key Companies - **EVE Energy**: Plans to produce nearly 500,000 battery cells annually after full production, with a focus on high-end applications such as humanoid robots and low-altitude aircraft [7]. Industry: Apple Foldable Devices Core Insights and Arguments - **Increased Production Estimates**: Apple has revised its foldable iPhone shipment estimates for 2026 and 2027 to 8-10 million and 20-25 million units, respectively [8]. - **Technological Innovations**: The new devices will utilize ultra-thin glass and liquid metal for hinges to enhance durability and reduce screen creasing [8]. Key Companies - **Yian Technology**: Reported to be the exclusive supplier of liquid metal hinge components for Apple [8]. Industry: Pharmaceutical Development Core Insights and Arguments - **New Drug Approvals**: Chenxin Pharmaceutical is advancing a new drug for drug-resistant tuberculosis, expected to apply for approval in 2025, with peak sales projected at 1-1.3 billion RMB [9][10]. Key Companies - **Baihua Pharmaceutical**: Focused on developing innovative drugs and enhancing its clinical research capabilities [14]. Industry: Photovoltaics Core Insights and Arguments - **Market Dynamics**: The price of polysilicon has increased, with mainstream prices reaching 55 RMB/kg for rod silicon and 49 RMB/kg for granular silicon [11]. - **Technological Advancements**: The company is investing in high-efficiency heterojunction solar cells and has achieved over 32% efficiency in laboratory tests for perovskite/heterojunction tandem cells [11]. Key Companies - **Baoxin Technology**: Actively developing high-efficiency heterojunction solar cells and expanding production bases [11]. Industry: Data Center Cooling Solutions Core Insights and Arguments - **Market Position**: Weilon Technology has supplied liquid cooling valves to major data centers, including Microsoft, with a projected revenue of $4 million in 2025 [12]. Key Companies - **Weilon Technology**: The only domestic supplier of valves to North American AIDC projects, leading the market by 1-2 years [12]. Risk Considerations - The information provided is for reference only, and the accuracy and completeness cannot be guaranteed. Investors should conduct their own research and make independent decisions [18].